<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782561</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-MC3019-026</org_study_id>
    <nct_id>NCT00782561</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)</brief_title>
  <official_title>A Phase I, Open-Label Study of the Safety and Pharmacokinetics of FG-3019 in Adolescent and Adult Subjects With Steroid-Resistant Focal Segmental Glomerulosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of FG-3019 administered
      over 8 weeks to adolescent and adult subjects with steroid-resistant focal segmental
      glomerulosclerosis (FSGS).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of FG-3019 as measured by AEs, SAEs, physical exams, lab tests, and the Treatment Satisfaction Questionnaire for Medications</measure>
    <time_frame>32 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standard plasma and urinary PK parameters</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urinary protein/creatinine, albumin/creatinine, albumin excretion rate, estimated glomerular filtration rate (eGFR), 24 hour urinary protein and fasting serum lipids</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Focal Segmental Glomerulosclerosis</condition>
  <arm_group>
    <arm_group_label>FG-3019</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FG-3019 5 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-3019</intervention_name>
    <description>FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks</description>
    <arm_group_label>FG-3019</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 12-64 years, inclusive, and girls age 10-11 years, inclusive if Tanner stage 3 or
             greater

          2. Biopsy diagnosis of primary FSGS with biopsy confirmed centrally

          3. Age less than or equal to 2 years old at onset of proteinuria

          4. First morning urine protein/creatinine ratio (U p/c) &gt;1 gm/gm

          5. Estimated glomerular filtration rate greater than or equal to 40 mL/min/1.73 m2

        Exclusion Criteria:

          1. Non-FSGS renal disease other than benign cyst; or secondary FSGS

          2. History of organ transplantation

          3. History of allergic or anaphylactic reaction to human, humanized, chimeric or murine
             monoclonal antibodies

          4. History of malignancy, cardiovascular disease, diabetes mellitus, sickle cell disease,
             multiple sclerosis, systemic lupus erythematosus, or active or recurrent serious
             infections (including but not limited to Hepatitis B, Hepatitis C, or HIV)

          5. Participation in studies of investigational drugs within 6 weeks prior to Day 0 or
             receipt of an investigational drug within 12 weeks prior to Day 0

          6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 2.5 times the
             upper limit of normal

          7. Hematocrit &lt; 30%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2008</study_first_submitted>
  <study_first_submitted_qc>October 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>July 14, 2009</last_update_submitted>
  <last_update_submitted_qc>July 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Claro Arzadon, Clinical Research Associate</name_title>
    <organization>FibroGen, Inc.</organization>
  </responsible_party>
  <keyword>steroid resistant focal segmental glomerulosclerosis</keyword>
  <keyword>FSGS</keyword>
  <keyword>adolescent focal segmental glomerulosclerosis</keyword>
  <keyword>focal segmental glomerulosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

